Abstract |
Psoriasis is a chronic immune-mediated disease that is characterized by the hyperproliferation and abnormal differentiation of keratinocytes and by inflammation. The epidermal changes associated with psoriasis may be due to the infiltration of inflammatory T lymphocytes and the release of cytokines in response to antigenic stimulation. Tazarotene is a retinoic acid receptor-specific retinoid with demonstrated efficacy in the topical treatment of psoriasis. Tazarotene down-regulates markers of keratinocyte differentiation, keratinocyte proliferation, and inflammation. The drug also up-regulates three novel genes TIG-1 (tazarotene-induced gene-1), TIG-2, and TIG-3, which may mediate an antiproliferative effect. The effect of tazarotene on these markers is probably a direct effect on gene expression rather than an indirect effect associated with disease improvement.
|
Authors | M Duvic, S Nagpal, A T Asano, R A Chandraratna |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 37
Issue 2 Pt 3
Pg. S18-24
(Aug 1997)
ISSN: 0190-9622 [Print] United States |
PMID | 9270552
(Publication Type: Journal Article, Review)
|
Chemical References |
- Dermatologic Agents
- Nicotinic Acids
- Prodrugs
- Retinoids
- tazarotene
|
Topics |
- Cell Differentiation
(drug effects)
- Cell Division
(drug effects)
- Dermatologic Agents
(pharmacology, therapeutic use)
- Humans
- Keratinocytes
(cytology, drug effects)
- Nicotinic Acids
(pharmacology, therapeutic use)
- Prodrugs
(pharmacology, therapeutic use)
- Psoriasis
(drug therapy, genetics, physiopathology)
- Retinoids
(pharmacology, therapeutic use)
- Skin
(drug effects)
|